6938 — Suzhou Ribo Life Science Co Income Statement
0.000.00%
Last trade - 00:00- HK$11.03bn
- HK$11.34bn
- CNY148.51m
Annual income statement for Suzhou Ribo Life Science Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PRESS |
| Standards: | IFRS | IFRS | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0.044 | 143 | 149 |
| Cost of Revenue | |||
| Gross Profit | -25 | 116 | 135 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 418 | 379 | 412 |
| Operating Profit | -418 | -237 | -263 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -437 | -257 | -285 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -437 | -281 | -288 |
| Minority Interest | |||
| Net Income Before Extraordinary Items | |||
| Net Income | -428 | -270 | -278 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -428 | -270 | -278 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -2.54 | -1.62 | -1.63 |